Global Immunotherapy Drugs for Neuroblastoma Market Research Report 2026(Status and Outlook)
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient"s age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
The global Immunotherapy Drugs for Neuroblastoma market size was estimated at USD 50.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Immunotherapy Drugs for Neuroblastoma market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Immunotherapy Drugs for Neuroblastoma market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Immunotherapy Drugs for Neuroblastoma market.
Global Immunotherapy Drugs for Neuroblastoma Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Market Segmentation (by Type)
Dinutuximab
Naxitamab
Other
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Immunotherapy Drugs for Neuroblastoma Market
Overview of the regional outlook of the Immunotherapy Drugs for Neuroblastoma Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immunotherapy Drugs for Neuroblastoma Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Immunotherapy Drugs for Neuroblastoma, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Immunotherapy Drugs for Neuroblastoma market size was estimated at USD 50.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Immunotherapy Drugs for Neuroblastoma market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Immunotherapy Drugs for Neuroblastoma market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Immunotherapy Drugs for Neuroblastoma market.
Global Immunotherapy Drugs for Neuroblastoma Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Market Segmentation (by Type)
Dinutuximab
Naxitamab
Other
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Immunotherapy Drugs for Neuroblastoma Market
Overview of the regional outlook of the Immunotherapy Drugs for Neuroblastoma Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immunotherapy Drugs for Neuroblastoma Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Immunotherapy Drugs for Neuroblastoma, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Key Market Segments
1.2.1 Immunotherapy Drugs for Neuroblastoma Segment by Type
1.2.2 Immunotherapy Drugs for Neuroblastoma Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Immunotherapy Drugs for Neuroblastoma Product Life Cycle
3.3 Global Immunotherapy Drugs for Neuroblastoma Sales by Manufacturers (2020-2025)
3.4 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2020-2025)
3.5 Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Immunotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
3.8.1 Immunotherapy Drugs for Neuroblastoma Market Concentration Rate
3.8.2 Global 5 and 10 Largest Immunotherapy Drugs for Neuroblastoma Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA INDUSTRY CHAIN ANALYSIS
4.1 Immunotherapy Drugs for Neuroblastoma Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Immunotherapy Drugs for Neuroblastoma Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Immunotherapy Drugs for Neuroblastoma Market
5.7 ESG Ratings of Leading Companies
6 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
6.3 Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (2020-2025)
6.4 Global Immunotherapy Drugs for Neuroblastoma Price by Type (2020-2025)
7 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Immunotherapy Drugs for Neuroblastoma Market Sales by Application (2020-2025)
7.3 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) by Application (2020-2025)
7.4 Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
8 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SALES BY REGION
8.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region
8.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region
8.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region
8.2 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.2.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.2.2 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.3 North America
8.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales by Country
8.3.2 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country
8.4.2 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region
8.5.2 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Immunotherapy Drugs for Neuroblastoma Sales by Country
8.6.2 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Region
8.7.2 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET PRODUCTION BY REGION
9.1 Global Production of Immunotherapy Drugs for Neuroblastoma by Region(2020-2025)
9.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
9.3 Global Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Immunotherapy Drugs for Neuroblastoma Production
9.4.1 North America Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.4.2 North America Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Immunotherapy Drugs for Neuroblastoma Production
9.5.1 Europe Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.5.2 Europe Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Immunotherapy Drugs for Neuroblastoma Production (2020-2025)
9.6.1 Japan Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.6.2 Japan Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Immunotherapy Drugs for Neuroblastoma Production (2020-2025)
9.7.1 China Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.7.2 China Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 United Therapeutics
10.1.1 United Therapeutics Basic Information
10.1.2 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
10.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.1.4 United Therapeutics Business Overview
10.1.5 United Therapeutics SWOT Analysis
10.1.6 United Therapeutics Recent Developments
10.2 Y-mAbs Therapeutics
10.2.1 Y-mAbs Therapeutics Basic Information
10.2.2 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
10.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.2.4 Y-mAbs Therapeutics Business Overview
10.2.5 Y-mAbs Therapeutics SWOT Analysis
10.2.6 Y-mAbs Therapeutics Recent Developments
10.3 EUSA Pharma
10.3.1 EUSA Pharma Basic Information
10.3.2 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Overview
10.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.3.4 EUSA Pharma Business Overview
10.3.5 EUSA Pharma SWOT Analysis
10.3.6 EUSA Pharma Recent Developments
10.4 ANI Pharmaceuticals
10.4.1 ANI Pharmaceuticals Basic Information
10.4.2 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.4.4 ANI Pharmaceuticals Business Overview
10.4.5 ANI Pharmaceuticals Recent Developments
10.5 Baxter Healthcare
10.5.1 Baxter Healthcare Basic Information
10.5.2 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Overview
10.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.5.4 Baxter Healthcare Business Overview
10.5.5 Baxter Healthcare Recent Developments
10.6 Ingenus Pharmaceuticals
10.6.1 Ingenus Pharmaceuticals Basic Information
10.6.2 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.6.4 Ingenus Pharmaceuticals Business Overview
10.6.5 Ingenus Pharmaceuticals Recent Developments
10.7 Pfizer
10.7.1 Pfizer Basic Information
10.7.2 Pfizer Immunotherapy Drugs for Neuroblastoma Product Overview
10.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.7.4 Pfizer Business Overview
10.7.5 Pfizer Recent Developments
10.8 Hikma Pharmaceuticals
10.8.1 Hikma Pharmaceuticals Basic Information
10.8.2 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.8.4 Hikma Pharmaceuticals Business Overview
10.8.5 Hikma Pharmaceuticals Recent Developments
10.9 Teva Pharmaceuticals
10.9.1 Teva Pharmaceuticals Basic Information
10.9.2 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.9.4 Teva Pharmaceuticals Business Overview
10.9.5 Teva Pharmaceuticals Recent Developments
11 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET FORECAST BY REGION
11.1 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast
11.2 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country
11.2.3 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region
11.2.4 South America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Immunotherapy Drugs for Neuroblastoma by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Immunotherapy Drugs for Neuroblastoma by Type (2026-2035)
12.1.2 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Immunotherapy Drugs for Neuroblastoma by Type (2026-2035)
12.2 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Application (2026-2035)
12.2.1 Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) Forecast by Application
12.2.2 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Key Market Segments
1.2.1 Immunotherapy Drugs for Neuroblastoma Segment by Type
1.2.2 Immunotherapy Drugs for Neuroblastoma Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Immunotherapy Drugs for Neuroblastoma Product Life Cycle
3.3 Global Immunotherapy Drugs for Neuroblastoma Sales by Manufacturers (2020-2025)
3.4 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2020-2025)
3.5 Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Immunotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
3.8.1 Immunotherapy Drugs for Neuroblastoma Market Concentration Rate
3.8.2 Global 5 and 10 Largest Immunotherapy Drugs for Neuroblastoma Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA INDUSTRY CHAIN ANALYSIS
4.1 Immunotherapy Drugs for Neuroblastoma Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Immunotherapy Drugs for Neuroblastoma Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Immunotherapy Drugs for Neuroblastoma Market
5.7 ESG Ratings of Leading Companies
6 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
6.3 Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (2020-2025)
6.4 Global Immunotherapy Drugs for Neuroblastoma Price by Type (2020-2025)
7 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Immunotherapy Drugs for Neuroblastoma Market Sales by Application (2020-2025)
7.3 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) by Application (2020-2025)
7.4 Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
8 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET SALES BY REGION
8.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region
8.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region
8.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region
8.2 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.2.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.2.2 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.3 North America
8.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales by Country
8.3.2 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country
8.4.2 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region
8.5.2 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Immunotherapy Drugs for Neuroblastoma Sales by Country
8.6.2 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Region
8.7.2 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET PRODUCTION BY REGION
9.1 Global Production of Immunotherapy Drugs for Neuroblastoma by Region(2020-2025)
9.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
9.3 Global Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Immunotherapy Drugs for Neuroblastoma Production
9.4.1 North America Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.4.2 North America Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Immunotherapy Drugs for Neuroblastoma Production
9.5.1 Europe Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.5.2 Europe Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Immunotherapy Drugs for Neuroblastoma Production (2020-2025)
9.6.1 Japan Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.6.2 Japan Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Immunotherapy Drugs for Neuroblastoma Production (2020-2025)
9.7.1 China Immunotherapy Drugs for Neuroblastoma Production Growth Rate (2020-2025)
9.7.2 China Immunotherapy Drugs for Neuroblastoma Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 United Therapeutics
10.1.1 United Therapeutics Basic Information
10.1.2 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
10.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.1.4 United Therapeutics Business Overview
10.1.5 United Therapeutics SWOT Analysis
10.1.6 United Therapeutics Recent Developments
10.2 Y-mAbs Therapeutics
10.2.1 Y-mAbs Therapeutics Basic Information
10.2.2 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
10.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.2.4 Y-mAbs Therapeutics Business Overview
10.2.5 Y-mAbs Therapeutics SWOT Analysis
10.2.6 Y-mAbs Therapeutics Recent Developments
10.3 EUSA Pharma
10.3.1 EUSA Pharma Basic Information
10.3.2 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Overview
10.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.3.4 EUSA Pharma Business Overview
10.3.5 EUSA Pharma SWOT Analysis
10.3.6 EUSA Pharma Recent Developments
10.4 ANI Pharmaceuticals
10.4.1 ANI Pharmaceuticals Basic Information
10.4.2 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.4.4 ANI Pharmaceuticals Business Overview
10.4.5 ANI Pharmaceuticals Recent Developments
10.5 Baxter Healthcare
10.5.1 Baxter Healthcare Basic Information
10.5.2 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Overview
10.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.5.4 Baxter Healthcare Business Overview
10.5.5 Baxter Healthcare Recent Developments
10.6 Ingenus Pharmaceuticals
10.6.1 Ingenus Pharmaceuticals Basic Information
10.6.2 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.6.4 Ingenus Pharmaceuticals Business Overview
10.6.5 Ingenus Pharmaceuticals Recent Developments
10.7 Pfizer
10.7.1 Pfizer Basic Information
10.7.2 Pfizer Immunotherapy Drugs for Neuroblastoma Product Overview
10.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.7.4 Pfizer Business Overview
10.7.5 Pfizer Recent Developments
10.8 Hikma Pharmaceuticals
10.8.1 Hikma Pharmaceuticals Basic Information
10.8.2 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.8.4 Hikma Pharmaceuticals Business Overview
10.8.5 Hikma Pharmaceuticals Recent Developments
10.9 Teva Pharmaceuticals
10.9.1 Teva Pharmaceuticals Basic Information
10.9.2 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
10.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Market Performance
10.9.4 Teva Pharmaceuticals Business Overview
10.9.5 Teva Pharmaceuticals Recent Developments
11 IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA MARKET FORECAST BY REGION
11.1 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast
11.2 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country
11.2.3 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region
11.2.4 South America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Immunotherapy Drugs for Neuroblastoma by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Immunotherapy Drugs for Neuroblastoma by Type (2026-2035)
12.1.2 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Immunotherapy Drugs for Neuroblastoma by Type (2026-2035)
12.2 Global Immunotherapy Drugs for Neuroblastoma Market Forecast by Application (2026-2035)
12.2.1 Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) Forecast by Application
12.2.2 Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (M USD)
Table 4. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application
Table 5. Immunotherapy Drugs for Neuroblastoma Market Size Comparison by Region (M USD)
Table 6. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Immunotherapy Drugs for Neuroblastoma Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Neuroblastoma as of 2025)
Table 11. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Immunotherapy Drugs for Neuroblastoma Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Immunotherapy Drugs for Neuroblastoma Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Immunotherapy Drugs for Neuroblastoma Sales by Type (K MT)
Table 27. Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (M USD)
Table 28. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Type (2020-2025)
Table 29. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Table 30. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) by Type (2020-2025)
Table 31. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type (2020-2025)
Table 32. Global Immunotherapy Drugs for Neuroblastoma Price (USD/KG) by Type (2020-2025)
Table 33. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Application
Table 34. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application
Table 35. Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K MT)
Table 36. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Table 37. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application (2020-2025) & (M USD)
Table 38. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application (2020-2025)
Table 39. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
Table 40. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 41. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Table 42. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 43. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025)
Table 44. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 45. North America Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 47. Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 50. South America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 51. South America Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 54. Global Immunotherapy Drugs for Neuroblastoma Production (K MT) by Region(2020-2025)
Table 55. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
Table 57. Global Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. United Therapeutics Basic Information
Table 63. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
Table 64. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. United Therapeutics Business Overview
Table 66. United Therapeutics SWOT Analysis
Table 67. United Therapeutics Recent Developments
Table 68. Y-mAbs Therapeutics Basic Information
Table 69. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
Table 70. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Y-mAbs Therapeutics Business Overview
Table 72. Y-mAbs Therapeutics SWOT Analysis
Table 73. Y-mAbs Therapeutics Recent Developments
Table 74. EUSA Pharma Basic Information
Table 75. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Overview
Table 76. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. EUSA Pharma Business Overview
Table 78. EUSA Pharma SWOT Analysis
Table 79. EUSA Pharma Recent Developments
Table 80. ANI Pharmaceuticals Basic Information
Table 81. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 82. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. ANI Pharmaceuticals Business Overview
Table 84. ANI Pharmaceuticals Recent Developments
Table 85. Baxter Healthcare Basic Information
Table 86. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Overview
Table 87. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Baxter Healthcare Business Overview
Table 89. Baxter Healthcare Recent Developments
Table 90. Ingenus Pharmaceuticals Basic Information
Table 91. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 92. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Ingenus Pharmaceuticals Business Overview
Table 94. Ingenus Pharmaceuticals Recent Developments
Table 95. Pfizer Basic Information
Table 96. Pfizer Immunotherapy Drugs for Neuroblastoma Product Overview
Table 97. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Pfizer Business Overview
Table 99. Pfizer Recent Developments
Table 100. Hikma Pharmaceuticals Basic Information
Table 101. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 102. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Hikma Pharmaceuticals Business Overview
Table 104. Hikma Pharmaceuticals Recent Developments
Table 105. Teva Pharmaceuticals Basic Information
Table 106. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 107. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Teva Pharmaceuticals Business Overview
Table 109. Teva Pharmaceuticals Recent Developments
Table 110. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2035) & (K MT)
Table 111. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region (2026-2035) & (M USD)
Table 112. North America Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 113. North America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 114. Europe Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 115. Europe Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 116. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2035) & (K MT)
Table 117. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region (2026-2035) & (M USD)
Table 118. South America Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 119. South America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 120. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (Units)
Table 121. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 122. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Type (2026-2035) & (K MT)
Table 123. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Type (2026-2035) & (M USD)
Table 124. Global Immunotherapy Drugs for Neuroblastoma Price Forecast by Type (2026-2035) & (USD/KG)
Table 125. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) Forecast by Application (2026-2035)
Table 126. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (M USD)
Table 4. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application
Table 5. Immunotherapy Drugs for Neuroblastoma Market Size Comparison by Region (M USD)
Table 6. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Immunotherapy Drugs for Neuroblastoma Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Neuroblastoma as of 2025)
Table 11. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Immunotherapy Drugs for Neuroblastoma Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Immunotherapy Drugs for Neuroblastoma Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Immunotherapy Drugs for Neuroblastoma Sales by Type (K MT)
Table 27. Global Immunotherapy Drugs for Neuroblastoma Market Size by Type (M USD)
Table 28. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Type (2020-2025)
Table 29. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Table 30. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) by Type (2020-2025)
Table 31. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type (2020-2025)
Table 32. Global Immunotherapy Drugs for Neuroblastoma Price (USD/KG) by Type (2020-2025)
Table 33. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) by Application
Table 34. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application
Table 35. Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K MT)
Table 36. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Table 37. Global Immunotherapy Drugs for Neuroblastoma Market Size by Application (2020-2025) & (M USD)
Table 38. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application (2020-2025)
Table 39. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
Table 40. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 41. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Table 42. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 43. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025)
Table 44. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 45. North America Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 47. Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 50. South America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K MT)
Table 51. South America Immunotherapy Drugs for Neuroblastoma Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025) & (M USD)
Table 54. Global Immunotherapy Drugs for Neuroblastoma Production (K MT) by Region(2020-2025)
Table 55. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
Table 57. Global Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Immunotherapy Drugs for Neuroblastoma Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. United Therapeutics Basic Information
Table 63. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
Table 64. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. United Therapeutics Business Overview
Table 66. United Therapeutics SWOT Analysis
Table 67. United Therapeutics Recent Developments
Table 68. Y-mAbs Therapeutics Basic Information
Table 69. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Overview
Table 70. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Y-mAbs Therapeutics Business Overview
Table 72. Y-mAbs Therapeutics SWOT Analysis
Table 73. Y-mAbs Therapeutics Recent Developments
Table 74. EUSA Pharma Basic Information
Table 75. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Overview
Table 76. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. EUSA Pharma Business Overview
Table 78. EUSA Pharma SWOT Analysis
Table 79. EUSA Pharma Recent Developments
Table 80. ANI Pharmaceuticals Basic Information
Table 81. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 82. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. ANI Pharmaceuticals Business Overview
Table 84. ANI Pharmaceuticals Recent Developments
Table 85. Baxter Healthcare Basic Information
Table 86. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Overview
Table 87. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Baxter Healthcare Business Overview
Table 89. Baxter Healthcare Recent Developments
Table 90. Ingenus Pharmaceuticals Basic Information
Table 91. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 92. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Ingenus Pharmaceuticals Business Overview
Table 94. Ingenus Pharmaceuticals Recent Developments
Table 95. Pfizer Basic Information
Table 96. Pfizer Immunotherapy Drugs for Neuroblastoma Product Overview
Table 97. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Pfizer Business Overview
Table 99. Pfizer Recent Developments
Table 100. Hikma Pharmaceuticals Basic Information
Table 101. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 102. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Hikma Pharmaceuticals Business Overview
Table 104. Hikma Pharmaceuticals Recent Developments
Table 105. Teva Pharmaceuticals Basic Information
Table 106. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Overview
Table 107. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Teva Pharmaceuticals Business Overview
Table 109. Teva Pharmaceuticals Recent Developments
Table 110. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2035) & (K MT)
Table 111. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region (2026-2035) & (M USD)
Table 112. North America Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 113. North America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 114. Europe Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 115. Europe Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 116. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2035) & (K MT)
Table 117. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region (2026-2035) & (M USD)
Table 118. South America Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (K MT)
Table 119. South America Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 120. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2035) & (Units)
Table 121. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Country (2026-2035) & (M USD)
Table 122. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Type (2026-2035) & (K MT)
Table 123. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Type (2026-2035) & (M USD)
Table 124. Global Immunotherapy Drugs for Neuroblastoma Price Forecast by Type (2026-2035) & (USD/KG)
Table 125. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) Forecast by Application (2026-2035)
Table 126. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD), 2025-2035
Figure 5. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) (2020-2035)
Figure 6. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Immunotherapy Drugs for Neuroblastoma Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Product Life Cycle
Figure 13. Immunotherapy Drugs for Neuroblastoma Sales Share by Manufacturers in 2025
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers in 2025
Figure 15. Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Immunotherapy Drugs for Neuroblastoma Revenue in 2025
Figure 18. Industry Chain Map of Immunotherapy Drugs for Neuroblastoma
Figure 19. Global Immunotherapy Drugs for Neuroblastoma Market PEST Analysis
Figure 20. Global Immunotherapy Drugs for Neuroblastoma Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type
Figure 27. Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2025)
Figure 28. Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type in 2025
Figure 29. Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2025)
Figure 30. Market Share of Immunotherapy Drugs for Neuroblastoma by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application
Figure 33. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 34. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application in 2025
Figure 35. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application (2020-2025)
Figure 36. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application in 2025
Figure 37. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
Figure 38. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Figure 39. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025)
Figure 40. North America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 43. North America Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 45. U.S. Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Immunotherapy Drugs for Neuroblastoma Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Immunotherapy Drugs for Neuroblastoma Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Immunotherapy Drugs for Neuroblastoma Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Immunotherapy Drugs for Neuroblastoma Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 53. Europe Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 55. Germany Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2024
Figure 67. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region in 2024
Figure 68. China Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 79. South America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 80. South America Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (M USD)
Figure 81. South America Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 82. Brazil Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region in 2024
Figure 92. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2020-2025)
Figure 103. North America Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 106. China Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Immunotherapy Drugs for Neuroblastoma Market Share Forecast by Type (2026-2035)
Figure 111. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Application (2026-2035)
Figure 112. Global Immunotherapy Drugs for Neuroblastoma Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD), 2025-2035
Figure 5. Global Immunotherapy Drugs for Neuroblastoma Market Size (M USD) (2020-2035)
Figure 6. Global Immunotherapy Drugs for Neuroblastoma Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Immunotherapy Drugs for Neuroblastoma Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Product Life Cycle
Figure 13. Immunotherapy Drugs for Neuroblastoma Sales Share by Manufacturers in 2025
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers in 2025
Figure 15. Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Immunotherapy Drugs for Neuroblastoma Revenue in 2025
Figure 18. Industry Chain Map of Immunotherapy Drugs for Neuroblastoma
Figure 19. Global Immunotherapy Drugs for Neuroblastoma Market PEST Analysis
Figure 20. Global Immunotherapy Drugs for Neuroblastoma Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type
Figure 27. Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2025)
Figure 28. Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type in 2025
Figure 29. Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2025)
Figure 30. Market Share of Immunotherapy Drugs for Neuroblastoma by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application
Figure 33. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 34. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application in 2025
Figure 35. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application (2020-2025)
Figure 36. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application in 2025
Figure 37. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate by Application (2020-2025)
Figure 38. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Figure 39. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (2020-2025)
Figure 40. North America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 43. North America Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 45. U.S. Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Immunotherapy Drugs for Neuroblastoma Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Immunotherapy Drugs for Neuroblastoma Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Immunotherapy Drugs for Neuroblastoma Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Immunotherapy Drugs for Neuroblastoma Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 53. Europe Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 55. Germany Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2024
Figure 67. Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region in 2024
Figure 68. China Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 79. South America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2024
Figure 80. South America Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (M USD)
Figure 81. South America Immunotherapy Drugs for Neuroblastoma Market Size by Country in 2024
Figure 82. Brazil Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Region in 2024
Figure 92. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Immunotherapy Drugs for Neuroblastoma Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Immunotherapy Drugs for Neuroblastoma Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Immunotherapy Drugs for Neuroblastoma Production Market Share by Region (2020-2025)
Figure 103. North America Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 106. China Immunotherapy Drugs for Neuroblastoma Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Immunotherapy Drugs for Neuroblastoma Market Share Forecast by Type (2026-2035)
Figure 111. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Application (2026-2035)
Figure 112. Global Immunotherapy Drugs for Neuroblastoma Market Share Forecast by Application (2026-2035)
